Revance Therapeutics Inc (RVNC)
5.80
-0.10
(-1.69%)
USD |
NASDAQ |
Nov 01, 16:00
5.795
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Enterprise Value: 802.59M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 802.59M |
| October 31, 2024 | 813.01M |
| October 30, 2024 | 815.09M |
| October 29, 2024 | 814.05M |
| October 28, 2024 | 813.01M |
| October 25, 2024 | 687.99M |
| October 24, 2024 | 750.50M |
| October 23, 2024 | 749.46M |
| October 22, 2024 | 749.46M |
| October 21, 2024 | 748.42M |
| October 18, 2024 | 749.46M |
| October 17, 2024 | 738.00M |
| October 16, 2024 | 748.42M |
| October 15, 2024 | 740.08M |
| October 14, 2024 | 733.83M |
| October 11, 2024 | 748.42M |
| October 10, 2024 | 746.33M |
| October 09, 2024 | 744.25M |
| October 08, 2024 | 742.16M |
| October 07, 2024 | 753.62M |
| October 04, 2024 | 742.16M |
| October 03, 2024 | 746.33M |
| October 02, 2024 | 739.04M |
| October 01, 2024 | 740.08M |
| September 30, 2024 | 739.04M |
| Date | Value |
|---|---|
| September 27, 2024 | 756.75M |
| September 26, 2024 | 759.87M |
| September 25, 2024 | 750.50M |
| September 24, 2024 | 770.81M |
| September 23, 2024 | 757.27M |
| September 20, 2024 | 803.63M |
| September 19, 2024 | 807.80M |
| September 18, 2024 | 822.38M |
| September 17, 2024 | 819.78M |
| September 16, 2024 | 820.30M |
| September 13, 2024 | 880.72M |
| September 12, 2024 | 881.77M |
| September 11, 2024 | 883.85M |
| September 10, 2024 | 882.81M |
| September 09, 2024 | 883.85M |
| September 06, 2024 | 883.85M |
| September 05, 2024 | 882.81M |
| September 04, 2024 | 883.85M |
| September 03, 2024 | 884.89M |
| August 30, 2024 | 882.81M |
| August 29, 2024 | 882.81M |
| August 28, 2024 | 883.85M |
| August 27, 2024 | 883.85M |
| August 26, 2024 | 883.85M |
| August 23, 2024 | 885.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
378.57M
Minimum
Apr 01 2020
3.267B
Maximum
May 09 2023
1.387B
Average
1.287B
Median
Aug 11 2020
Enterprise Value Benchmarks
| Recursion Pharmaceuticals Inc | 1.363B |
| Moderna Inc | 12.51B |
| Pacira BioSciences Inc | 949.40M |
| PetIQ Inc | -- |
| Anebulo Pharmaceuticals Inc | 44.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -37.47M |
| Revenue (Quarterly) | 65.39M |
| Total Expenses (Quarterly) | 99.90M |
| EPS Diluted (Quarterly) | -0.36 |
| Gross Profit Margin (Quarterly) | 73.03% |
| Profit Margin (Quarterly) | -57.31% |
| Earnings Yield | -55.17% |
| Normalized Earnings Yield | -39.60 |